CCA
DXCM icon

Catalyst Capital Advisors’s DexCom DXCM Stock Holding History

Catalyst Capital Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.6K Buy
1,390
+15
+1% +$999 ﹤0.01% 243
2026
Q1 		$86.3K Buy
1,375
+1,151
+514% +$80.2K ﹤0.01% 258
2025
Q4 		$14.9K Buy
224
+27
+14% +$1.75K ﹤0.01% 362
2025
Q3 		$13.3K Sell
197
-44
-18% -$3.48K ﹤0.01% 436
2025
Q2 		$21K Sell
241
-63
-21% -$4.94K ﹤0.01% 437
2025
Q1 		$20.8K Sell
304
-729
-71% -$59.5K ﹤0.01% 409
2024
Q4 		$80.3K Buy
1,033
+726
+236% +$53.8K ﹤0.01% 329
2024
Q3 		$20.6K Sell
307
-78
-20% -$6.41K ﹤0.01% 449
2024
Q2 		$43.7K Buy
385
+15
+4% +$1.9K ﹤0.01% 259
2024
Q1 		$51.3K Buy
370
+6
+2% +$754 ﹤0.01% 244
2023
Q4 		$45.2K Buy
364
+77
+27% +$7.87K ﹤0.01% 228
2023
Q3 		$26.8K Buy
287
+74
+35% +$8.34K ﹤0.01% 295
2023
Q2 		$27.4K Sell
213
-18
-8% -$2.18K ﹤0.01% 292
2023
Q1 		$26.8K Sell
231
-71
-24% -$7.95K ﹤0.01% 279
2022
Q4 		$34.2K Sell
302
-11
-4% -$1.21K ﹤0.01% 269
2022
Q3 		$25K Buy
313
+1
+0.3% +$85 ﹤0.01% 299
2022
Q2 		$23K Buy
312
+44
+16% +$4.02K ﹤0.01% 316
2022
Q1 		$34K Buy
268
+52
+24% +$5.69K ﹤0.01% 342
2021
Q4 		$29K Sell
216
-16
-7% -$2.3K ﹤0.01% 333
2021
Q3 		$32K Sell
232
-4
-2% -$504 ﹤0.01% 318
2021
Q2 		$25K Buy
236
+8
+4% +$768 ﹤0.01% 348
2021
Q1 		$20K Sell
228
-44
-16% -$4.13K ﹤0.01% 324
2020
Q4 		$25K Sell
272
-75,728
-100% -$6.76M ﹤0.01% 300
2020
Q3 		$7.83M Sell
76,000
-4,800
-6% -$501K 0.44% 33
2020
Q2 		$8.19M Buy
80,800
+18,800
+30% +$1.68M 0.42% 33
2020
Q1 		$4.17M Buy
+62,000
New +$3.86M 0.21% 67

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Catalyst Capital Advisors's DXCM Position: Q2 2026 in Review

Catalyst Capital Advisors increased its DexCom (DXCM) stake by 1.1% in Q2 2026, buying an estimated $999 and bringing the position to 1,390 shares worth $93.6K. The position accounts for ﹤0.01% of the portfolio, ranked #243.

Catalyst Capital Advisors first reported a position in DXCM in Q1 2020 and has held it in 26 quarters since. The position peaked at $8.19M in Q2 2020. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Catalyst Capital Advisors held 1,390 shares of DexCom worth $93.6K as of Q2 2026.
  • Catalyst Capital Advisors bought 15 DexCom shares in Q2 2026, an estimated $999.
  • DexCom made up ﹤0.01% of Catalyst Capital Advisors's portfolio in Q2 2026, its #243 holding.
  • Catalyst Capital Advisors first reported a position in DexCom in Q1 2020 and has held it in 26 quarters since.
  • Catalyst Capital Advisors's DexCom position peaked at $8.19M in Q2 2020.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.